Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-041 in HFpEF
NCT07219511Phase 1Active, not recruiting
- Sponsor
- Vasa Therapeutics
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VS-041 in heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by Vasa Therapeutics. Primary endpoints: Participant incidence of treatment-emergent adverse events at 28 days, Change from baseline over time in serum NordicPRO-C6 at 28 days and 2 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
VS-041
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07219511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219511.